Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 10lutetium Lu 177 dotatate 8cabozantinib 4Nivolumab 4Cisplatin 4pembrolizumab 3X-Rays 3Ipilimumab 3Everolimus 3Etoposide 3Carboplatin 3olaparib 2gallium Ga 68 dotatate 2fluorodopa F 18 2fludarabine 2aldesleukin 2Phantoms, Imaging 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 2Cyclophosphamide 2CTLA-4 Antigen 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
selpercatinib × Endocrine × 30 days × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡